Saluda Medical Inc · ASX:SLD
Saluda Medical — Q2 FY26 Earnings Presentation
10 slides from Saluda Medical's earnings presentation, Jan 28, 2026
Slide 1: Saluda Medical Update
For personal use only Saluda Medical Update January 28th, 2026 Weare on a Mission to Transform Patients’ Lives with Revolutionary Neural-Sensing Technology
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS DOCUMENT AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIB
Slide 3: Spinal Cord Stimulation (SCS) is an Established Market
Spinal Cord Stimulation (SCS) is an Established Market SCS represents a substantial opportunity which remains significantly underserved For personal use only Annual cost of chronic pain in ~24% of American Adults2 US exceed costs of heart disease, cancer and diabetes1 have chronic pain ~6% Estimated
Slide 4: Traditional Fixed Dose SCS for Chronic Pain
Traditional Fixed Dose SCS for Chronic Pain Well-established therapy for the treatment of chronic neurological pain For personal use only 4 Patient adjusts stimulation with remote control 30+ times per day1 SCS leads are implanted near the spinal cord to deliver electrical 3 stimulation from an impl
Slide 5: Saluda Medical | Personalised, Closed-Loop Technology
Saluda Medical | Personalised, Closed-Loop Technology Saluda Medical’s three major breakthroughs represent a paradigm shift in SCS therapy For personal use only 1 Enables personalised closed- loop SCS to deliver life changing Measures the nerve’s response improvements in pain to stimulation manageme
Slide 6: Breakthrough Clinical Data, Patient Outcomes & Therapy Burden
Breakthrough Clinical Data, Patient Outcomes & Therapy Burden Backed by the world’s only double-blinded trial in SCS conducted over 3 years For personal use only Closed-loop system reads, measures OUTCOME HIGHLIGHTS and responds to patient-specific needs Ensures accurate physiologic dosing in real-t
Slide 7: Q2 FY26 Quarterly Activity Report
Q2 FY26 Quarterly Activity Report ASX announcement highlights For personal use only ▪ Saluda lists on ASX 5 December 2025, following a A$230.8m (~US$150m) IPO ▪ Global and US commercial momentum achieved in both Q2 FY26 and H1 FY26, including: ▪ Acceleration in global revenue growth, driven by incre
Slide 8: Q2 FY26 Quarterly Activity Report
Q2 FY26 Quarterly Activity Report ASX announcement highlights For personal use only ▪ Strong representation at the January 2026 North American Neuromodulation Society (NANS) annual meeting, with 19 clinical abstracts and 5 oral presentations, showing continued societal and customer interest in close
Slide 9: Q2 FY26 / H1 FY26 revenue and select US commercial metrics
Q2 FY26 Quarterly Activity Report Q2 FY26 / H1 FY26 revenue and select US commercial metrics For personal use only Q2 Q2 Growth vs. H1 H1 Growth vs. FY26 FY25 PCP FY26 FY25 PCP US Revenue ($m) 15.4 13.2 16.9% 28.4 25.0 13.6% Int’l Revenue ($m) 5.6 4.4 29.1% 11.0 8.7 26.8% Total Revenue ($m) 21.0 17.
Slide 10: Everything Changes. This Changes Everything.
For personal use only EVERYTHING CHANGES. THIS CHANGES EVERYTHING. Therapy as Dynamic as Life.